Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
RiMO-401 by Coordination Pharmaceuticals for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
RiMO-401 is under clinical development by Coordination Pharmaceuticals and currently in Phase I for Head And Neck Squamous Cell Carcinoma...